Semaglutide in children aged 6 to under 12
In 167 children aged 6 to under 12 with obesity, weekly semaglutide reduced BMI by 13.5% versus a 2.7% increase with placebo at 68 weeks in the primary analysis. Both groups received lifestyle support.
Semaglutide remains investigational in this age group. Children weighed more than 45 kg; dosing depended on weight and tolerability. Gastrointestinal symptoms were more frequent with semaglutide and led one participant to stop treatment. Longer-term growth and safety remain important.
Study design, results and safety
The trial randomized 167 children with obesity to weekly semaglutide (112) or placebo (55), both with lifestyle intervention. The registry required body weight >45 kg. Novo describes target maximum weekly doses of 1.7 mg at 45–60 kg and 2.4 mg above 60 kg, or the maximum tolerated dose. These data do not establish dosing in children weighing 45 kg or less.
At week 68, primary treatment-regimen BMI change was −13.5% versus +2.7%: difference −16.2 percentage points (95% CI −19.4 to −12.9). The separate efficacy-estimand estimates were −17.4% versus +2.2%: difference −19.7 points (−23.1 to −16.2).
At week 104, supportive treatment-regimen BMI changes were −9.4% versus +8.4%; the separate efficacy estimates were −14.0% versus +5.7%. These secondary results were not adjusted for multiplicity. Interpretation of the difference from week 68 requires the extension’s adherence and missing-data context.
The September finding that 40.4% versus 0% fell below the pediatric obesity threshold was already public and belongs to the efficacy analysis. Adult BMI cutoffs do not define obesity in growing children.
Safety: The journal abstract reports adverse events in 96% with semaglutide and 93% with placebo. GI events were the most common and occurred more frequently with semaglutide; they led to discontinuation in one semaglutide participant. These are not rates of persistent or severe GI symptoms. Longer-term growth, maturation and tolerability remain important when interpreting pediatric evidence.
Clinical context: Randomized evidence is expanding into younger ages. This is not a comparison with another medicine; semaglutide remains investigational for this age group.

